Compare LFST & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LFST | EVO |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 895.8M |
| IPO Year | 2021 | N/A |
| Metric | LFST | EVO |
|---|---|---|
| Price | $6.25 | $2.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $9.71 | $7.00 |
| AVG Volume (30 Days) | ★ 2.2M | 110.9K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $1,424,285,000.00 | N/A |
| Revenue This Year | $17.18 | N/A |
| Revenue Next Year | $14.02 | $7.13 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 13.85 | N/A |
| 52 Week Low | $3.74 | $2.31 |
| 52 Week High | $8.09 | $4.80 |
| Indicator | LFST | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 37.72 | 32.84 |
| Support Level | $6.16 | $2.31 |
| Resistance Level | $6.63 | $3.75 |
| Average True Range (ATR) | 0.20 | 0.08 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 8.49 | 21.76 |
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family, and group therapy. It treats a broad range of mental health conditions, including anxiety, depression, bipolar disorder, eating disorders, psychotic disorders, and post-traumatic stress disorder, using evidence-based approaches to ensure effective treatment. The group has a single operating and reportable segment of mental health services.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.